Stock BSX BOSTON SCIENTIFIC CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Financials Boston Scientific Corporation

Equities

BSX

US1011371077

Advanced Medical Equipment & Technology

Market Closed - Nyse
Other stock markets
 04:00:02 2024-05-23 pm EDT 		5-day change 1st Jan Change
74.38 USD -1.31% Intraday chart for Boston Scientific Corporation -0.23% +28.66%
May. 23 Boston Scientific Insider Sold Shares Worth $2,504,239, According to a Recent SEC Filing MT
May. 23 Medtronic beats quarterly profit estimates on medical devices strength RE

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 63,029 51,478 60,534 66,273 84,691 109,352 - -
Enterprise Value (EV) 1 72,820 58,887 67,674 74,280 92,928 115,803 113,044 109,336
P/E ratio 13.6 x -300 x 61.6 x 103 x 54 x 50.6 x 41.1 x 34.2 x
Yield - - - - - - - -
Capitalization / Revenue 5.87 x 5.19 x 5.09 x 5.23 x 5.95 x 6.84 x 6.22 x 5.67 x
EV / Revenue 6.78 x 5.94 x 5.69 x 5.86 x 6.53 x 7.24 x 6.43 x 5.67 x
EV / EBITDA 23.4 x 19.4 x 16.5 x 20.8 x 22.6 x 24.9 x 21.5 x 18.5 x
EV / FCF 53 x 52 x 51.4 x 79.2 x 51.9 x 51.4 x 38.8 x 28.3 x
FCF Yield 1.89% 1.92% 1.94% 1.26% 1.93% 1.94% 2.58% 3.54%
Price to Book 4.54 x 3.32 x 3.64 x 3.77 x 4.39 x 5.11 x 4.53 x 3.91 x
Nbr of stocks (in thousands) 1,393,824 1,431,921 1,424,992 1,432,311 1,464,983 1,470,180 - -
Reference price 2 45.22 35.95 42.48 46.27 57.81 74.38 74.38 74.38
Announcement Date 2/5/20 2/3/21 2/2/22 2/1/23 1/31/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 10,735 9,913 11,888 12,682 14,240 15,987 17,572 19,280
EBITDA 1 3,111 3,040 4,103 3,574 4,106 4,644 5,263 5,914
EBIT 1 2,800 1,917 3,010 3,241 3,738 4,276 4,797 5,385
Operating Margin 26.08% 19.34% 25.32% 25.56% 26.25% 26.75% 27.3% 27.93%
Earnings before Tax (EBT) 1 687 -138 1,076 1,141 1,985 2,628 3,271 3,868
Net income 1 4,700 -173 985 642 1,570 2,201 2,733 3,271
Net margin 43.78% -1.75% 8.29% 5.06% 11.03% 13.76% 15.56% 16.96%
EPS 2 3.330 -0.1200 0.6900 0.4500 1.070 1.471 1.811 2.175
Free Cash Flow 1 1,375 1,132 1,316 938 1,792 2,251 2,915 3,865
FCF margin 12.81% 11.42% 11.07% 7.4% 12.58% 14.08% 16.59% 20.05%
FCF Conversion (EBITDA) 44.2% 37.24% 32.07% 26.25% 43.64% 48.47% 55.4% 65.36%
FCF Conversion (Net income) 29.26% - 133.6% 146.11% 114.14% 102.29% 106.66% 118.17%
Dividend per Share 2 - - - - - - - -
Announcement Date 2/5/20 2/3/21 2/2/22 2/1/23 1/31/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 3,127 3,026 3,244 3,170 3,242 3,389 3,599 3,527 3,725 3,856 4,018 3,954 4,173 4,227 4,421
EBITDA 1 1,109 1,055 898 892 928 947 1,052 1,011 1,095 1,316 1,142 1,133 1,221 1,321 1,324
EBIT 1 819 781 818 810 833 865 964 919 990 1,012 1,071 1,054 1,139 1,130 1,207
Operating Margin 26.19% 25.81% 25.22% 25.55% 25.69% 25.52% 26.79% 26.06% 26.58% 26.24% 26.66% 26.64% 27.31% 26.72% 27.31%
Earnings before Tax (EBT) 1 120 156 345 245 396 444 426 610 505 608 738.8 744 777.2 709 781
Net income 1 80 97 246 174 126 300 261 505 504 495 539.6 516.6 590.7 621.8 676.7
Net margin 2.56% 3.21% 7.58% 5.49% 3.89% 8.85% 7.25% 14.32% 13.53% 12.84% 13.43% 13.06% 14.16% 14.71% 15.31%
EPS 2 0.0600 0.0700 0.1700 0.1200 0.0900 0.2100 0.1800 0.3400 0.3400 0.3300 0.3603 0.3453 0.3988 0.4102 0.4462
Dividend per Share 2 - - - - - - - - - - - - - - -
Announcement Date 2/2/22 4/27/22 7/27/22 10/26/22 2/1/23 4/26/23 7/27/23 10/26/23 1/31/24 4/24/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 9,791 7,409 7,140 8,007 8,237 6,451 3,692 -
Net Cash position 1 - - - - - - - 15.9
Leverage (Debt/EBITDA) 3.147 x 2.437 x 1.74 x 2.24 x 2.006 x 1.389 x 0.7015 x -
Free Cash Flow 1 1,375 1,132 1,316 938 1,792 2,251 2,915 3,865
ROE (net income / shareholders' equity) 19.8% 9.44% 14.1% 14.4% 16.3% 16.3% 17% 16.5%
ROA (Net income/ Total Assets) 8.67% 4.49% 7.42% 7.6% 8.87% 8.41% 9.35% 8.2%
Assets 1 54,241 -3,851 13,284 8,446 17,696 26,174 29,223 39,888
Book Value Per Share 2 9.950 10.80 11.70 12.30 13.20 14.60 16.40 19.00
Cash Flow per Share 2 1.300 1.060 1.300 1.060 1.710 2.590 2.970 3.440
Capex 1 461 376 554 588 711 692 735 776
Capex / Sales 4.29% 3.79% 4.66% 4.64% 4.99% 4.33% 4.18% 4.03%
Announcement Date 2/5/20 2/3/21 2/2/22 2/1/23 1/31/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Boston Scientific Corporation

Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
31
Last Close Price
74.38 USD
Average target price
81.53 USD
Spread / Average Target
+9.62%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

1st Jan change Capi.
BOSTON SCIENTIFIC CORPORATION Stock Boston Scientific Corporation
+28.66% 109B
THERMO FISHER SCIENTIFIC Stock Thermo Fisher Scientific
+10.22% 223B
DANAHER CORPORATION Stock Danaher Corporation
+12.99% 194B
INTUITIVE SURGICAL, INC. Stock Intuitive Surgical, Inc.
+18.09% 141B
SIEMENS HEALTHINEERS AG Stock Siemens Healthineers AG
+2.09% 64.85B
EDWARDS LIFESCIENCES CORPORATION Stock Edwards Lifesciences Corporation
+14.70% 52.7B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD. Stock Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
+6.68% 51.77B
AGILENT TECHNOLOGIES, INC. Stock Agilent Technologies, Inc.
+8.29% 44.12B
GE HEALTHCARE TECHNOLOGIES INC. Stock GE HealthCare Technologies Inc.
+2.60% 36.21B
RESMED, INC. Stock ResMed, Inc.
+23.00% 31.08B
Other Advanced Medical Equipment & Technology
  1. Stock Market
  2. Equities
  3. BSX Stock
  4. Financials Boston Scientific Corporation